Insider Selling: Tempus AI (NASDAQ:TEM) CAO Sells $97,050.80 in Stock

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CAO Ryan Bartolucci sold 1,540 shares of the stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $97,050.80. Following the completion of the transaction, the chief accounting officer directly owned 59,264 shares of the company’s stock, valued at approximately $3,734,817.28. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

Shares of NASDAQ TEM traded down $4.01 during mid-day trading on Thursday, hitting $59.61. 5,290,938 shares of the stock were exchanged, compared to its average volume of 6,229,094. The stock’s fifty day simple moving average is $72.87 and its two-hundred day simple moving average is $57.56. The company has a debt-to-equity ratio of 2.70, a quick ratio of 2.48 and a current ratio of 2.61. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $89.09. The company has a market cap of $10.87 billion, a P/E ratio of -56.24 and a beta of 3.61.

Tempus AI (NASDAQ:TEM – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The firm had revenue of $411.54 million for the quarter, compared to analyst estimates of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The company’s revenue was up 23.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.46) EPS. As a group, analysts forecast that Tempus AI, Inc. will post -1.20 EPS for the current fiscal year.

Tempus AI News Summary

These are some of the TEM news items that stood out recently:

  • Positive Sentiment: Tempus will present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium. The research exposure could showcase its oncology data and precision-medicine capabilities, though the headline does not disclose results or commercial impact. Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
  • Positive Sentiment: Tempus and AstraZeneca extended their strategic services agreement through a fifth amendment. The expanded relationship may support Tempus’s data and services business and validates its capabilities with a major pharmaceutical partner; the supplied summaries do not specify the financial terms. Tempus AI and AstraZeneca Extend Strategic Services Agreement
  • Positive Sentiment: A recent investor-focused article cites data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027. These figures offer potential revenue support, although they depend on execution and timing. Tempus AI: 3 Key Takeaways for Long-Term Investors

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TEM shares. Cantor Fitzgerald raised their price target on Tempus AI from $80.00 to $92.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Guggenheim increased their price target on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Jefferies Financial Group upgraded Tempus AI from an “underperform” rating to a “hold” rating and lifted their target price for the stock from $35.00 to $70.00 in a research note on Tuesday, November 3rd. Finally, The Goldman Sachs Group began coverage on Tempus AI in a research report on Monday, September 21st. They issued a “neutral” rating and a $75.00 price target for the company. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.37.

Read Our Latest Stock Report on Tempus AI

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. V Square Quantitative Management LLC purchased a new stake in Tempus AI during the 3rd quarter valued at $27,000. EMC Capital Management purchased a new stake in shares of Tempus AI in the 2nd quarter worth approximately $29,000. Edmond DE Rothschild Holding S.A. bought a new stake in Tempus AI in the third quarter worth $33,000. Ulland Investment Advisors LLC purchased a new stake in shares of Tempus AI in the third quarter worth $41,000. Finally, Heritage Family Offices LLP purchased a new position in shares of Tempus AI in the 3rd quarter worth about $45,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Featured Articles

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.